Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 22, 2026
DataAggregated Company Financials
Companies110
  • 7D-2.1%
  • 3M3.6%
  • 1Y-16.2%
  • YTD-10.3%

Over the last 7 days, the Personal Products industry has dropped 2.1%, driven by a pullback from Estée Lauder Companies of 5.8%. In contrast, SL Science Holding has gained 74%. The industry has fallen 16% in the last year. As for the next few years, earnings are expected to grow by 33% per annum.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 22 Jun 2026US$83.2bUS$48.3bUS$693.7m17.6x119.9x1.7x
Wed, 20 May 2026US$76.9bUS$48.2bUS$833.1m15.7x92.3x1.6x
Fri, 17 Apr 2026US$78.0bUS$48.2bUS$613.7m21.8x127.2x1.6x
Sun, 15 Mar 2026US$81.9bUS$48.2bUS$678.5m22.1x120.7x1.7x
Tue, 10 Feb 2026US$90.1bUS$48.1bUS$993.9m21.1x90.6x1.9x
Thu, 08 Jan 2026US$90.1bUS$47.6bUS$350.4m21.3x257.2x1.9x
Sat, 06 Dec 2025US$89.6bUS$47.6bUS$351.1m23.6x255.3x1.9x
Mon, 03 Nov 2025US$85.4bUS$47.8bUS$493.6m21x173x1.8x
Wed, 01 Oct 2025US$90.1bUS$47.7bUS$307.3m20.8x293.2x1.9x
Fri, 29 Aug 2025US$100.9bUS$47.6bUS$303.5m22.6x332.4x2.1x
Sun, 27 Jul 2025US$103.7bUS$48.1bUS$108.8m21.2x953x2.2x
Tue, 24 Jun 2025US$96.4bUS$48.0bUS$109.5m16.6x879.9x2x
Thu, 22 May 2025US$95.4bUS$48.0bUS$113.3m17.5x841.7x2x
Sat, 19 Apr 2025US$84.4bUS$48.7bUS$556.7m23x151.7x1.7x
Mon, 17 Mar 2025US$90.7bUS$48.6bUS$350.0m30.2x259.3x1.9x
Wed, 12 Feb 2025US$89.3bUS$49.0bUS$368.8m23.1x242.1x1.8x
Fri, 10 Jan 2025US$96.1bUS$49.3bUS$1.5b27.3x65.1x2x
Sun, 08 Dec 2024US$104.6bUS$49.3bUS$1.5b29.2x71x2.1x
Tue, 05 Nov 2024US$96.7bUS$49.3bUS$1.4b25.8x67.3x2x
Thu, 03 Oct 2024US$111.9bUS$49.5bUS$1.6b26.6x68.5x2.3x
Sat, 31 Aug 2024US$108.5bUS$49.5bUS$1.6b22.1x66.2x2.2x
Mon, 29 Jul 2024US$108.8bUS$48.9bUS$2.4b22.8x45.1x2.2x
Wed, 26 Jun 2024US$114.7bUS$49.0bUS$2.4b21.6x47.3x2.3x
Fri, 24 May 2024US$118.8bUS$49.0bUS$2.4b19.8x49x2.4x
Sun, 21 Apr 2024US$124.7bUS$48.8bUS$2.5b25.1x49.2x2.6x
Tue, 19 Mar 2024US$132.4bUS$48.7bUS$2.5b24.6x52.7x2.7x
Thu, 15 Feb 2024US$126.0bUS$49.2bUS$2.6b23.6x49.2x2.6x
Sat, 13 Jan 2024US$126.4bUS$49.9bUS$2.6b26.7x48x2.5x
Mon, 11 Dec 2023US$120.8bUS$49.9bUS$2.6b26.5x45.9x2.4x
Wed, 08 Nov 2023US$106.3bUS$49.6bUS$2.8b24.8x37.5x2.1x
Fri, 06 Oct 2023US$118.3bUS$50.0bUS$3.3b23.6x36.1x2.4x
Sun, 03 Sep 2023US$137.2bUS$50.0bUS$3.3b21x41.8x2.7x
Tue, 01 Aug 2023US$146.4bUS$49.8bUS$3.1b26.1x48x2.9x
Thu, 29 Jun 2023US$151.6bUS$49.3bUS$3.1b22x48.3x3.1x
Price to Earnings Ratio

48.3x


Total Market Cap: US$151.6bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 172.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 120x which is lower than its 3-year average PE of 172x.
  • The 3-year average PS ratio of 2.2x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 40% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market1.40%
Consumer Staples-2.86%
Personal Products-2.14%
Personal Products-2.14%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SLBT SL Science HoldingUS$5.7973.9%
+US$397.6m		-43.3%n/a
ODD Oddity TechUS$13.0713.1%
+US$85.6m		-82.3%PE14.4x
BRBR BellRing BrandsUS$9.466.8%
+US$69.8m		-84.1%PE7x
HNST Honest CompanyUS$3.775.3%
+US$20.9m		-22.3%PS1.2x
ELF e.l.f. BeautyUS$64.200.3%
+US$12.5m		-47.9%PE145x

Latest News

EL
US$84.81
Estée Lauder Companies
7D
-5.8%
1Y
7.6%
COTY
US$1.95
Coty
7D
-4.9%
1Y
-59.5%
BRBR
US$9.46
BellRing Brands
7D
6.8%
1Y
-84.1%
Analysis Article • Jun 21

BellRing Brands (BRBR) Stock Could Be 69.9% Below Fair Value Despite Margin Pressure

Recent commentary on BellRing Brands (BRBR) has focused on slowing revenue growth and thinner margins as costs rise and competition intensifies. This has prompted fresh questions about the stock’s recent share price performance. See our latest analysis for BellRing Brands. Over the past year, BellRing Brands has seen the share price fall sharply, with a year to date share price return of down 63.74% and a 1 year total shareholder return of down 83.91%. Short term momentum has picked up, with...
IPAR
US$99.09
Interparfums
7D
-0.3%
1Y
-26.5%
Analysis Article • Jun 19

Interparfums (IPAR) Stock Could Be 9.4% Undervalued After Institutional Buying

Interparfums (IPAR) is back in focus after recent data showed institutional investors now hold 66.49% of the company, with largest shareholder Chuck Royce significantly increasing his position last quarter. See our latest analysis for Interparfums. Interparfums’ recent 1 month share price return of 9.77% and 3 month share price return of 10.15%, taking the stock to US$99.09, contrast with a 1 year total shareholder return that declined 22.5%. This suggests improving short term momentum after...
USNA
US$18.88
USANA Health Sciences
7D
-2.7%
1Y
-37.8%
Seeking Alpha • Jun 19

USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy

Summary USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2. I assign USNA a Buy rating with a $30.8/share target, citing undervaluation (1.92x forward EV/EBITDA) and strong cash position. Read the full article on Seeking Alpha
YSG
US$3.20
Yatsen Holding
7D
-4.5%
1Y
-66.4%
Narrative Update • Jun 18

YSG: Higher Margin Outlook And Buybacks Will Support Future Upside

Analysts have nudged their price target on Yatsen Holding slightly higher to $9.44 from $9.28, citing updated assumptions that combine a modestly lower revenue growth outlook with a higher expected profit margin and a reduced future P/E multiple. What’s in the News for Yatsen Holding Yatsen Holding issued revenue guidance for the second quarter of 2026, indicating expected total net revenues between RMB1.20b and RMB1.30b, based on its current view of market and operational conditions.
ELF
US$64.20
e.l.f. Beauty
7D
0.3%
1Y
-47.9%
Narrative Update • Jun 17

ELF: Rhode Expansion And Price Resets Will Support Future Upside

e.l.f. Beauty's analyst price target in this update shifts from $129.85 to $90.00 as analysts broadly reset expectations around valuation multiples and core cosmetics momentum, even as they highlight contributions from Rhode, skincare, and category expansions such as hair care. Analyst Commentary Recent research on e.l.f. Beauty highlights a mixed but constructive backdrop, with several firms trimming valuation assumptions while still pointing to earnings power from Rhode, skincare, and new categories like hair care.
ODD
US$13.07
Oddity Tech
7D
13.1%
1Y
-82.3%
Narrative Update • Jun 17

ODD: Advertising Disruptions And Rising Acquisition Costs Will Pressure Shares

Oddity Tech's analyst fair value estimate has been reduced from $40.00 to $8.00. This reflects a broad reset in Street price targets as analysts factor in higher discount rates, much lower modeled revenue growth and profit margins, and a sharply higher future P/E multiple after recent advertising and earnings challenges.
EPC
US$23.11
Edgewell Personal Care
7D
0.5%
1Y
-4.0%
Seeking Alpha • Jun 17

Edgewell: How Exiting Feminine Care Makes It A Buy Opportunity

Summary Edgewell Personal Care is rated Buy, with a $30/share target, following its strategic exit from the feminine care segment and debt reduction. EPC's focus on high-margin wet shaving, sun, and men's grooming segments, especially CREMO's 38% growth, is driving a leaner, more profitable business model. Short-term margin pressures from inflation and tariffs are expected to ease in H2 as restructuring and productivity initiatives reach full effect. Key risks include inflationary shipping/material costs, factory consolidation execution, and Q3's heavy reliance on seasonal sun care sales. Read the full article on Seeking Alpha
HNST
US$3.77
Honest Company
7D
5.3%
1Y
-22.3%
Narrative Update • Jun 16

HNST: Improving Margins And Buybacks Will Support Future Stock Re Rating

The Honest Company stock price target has been adjusted modestly higher, with analysts citing updated valuation work that reflects a slightly different discount rate, revenue outlook, profit margin profile, and future P/E assumptions consistent with recent target increases of $0.40, $0.50, and $1.00 from Street research. Analyst Commentary Recent price target revisions for Honest Company stock point to a more constructive tone from bullish analysts, who are updating models to reflect refreshed assumptions around growth, profitability, and P/E levels rather than any single short term event.
WALD
US$1.66
Waldencast
7D
-8.8%
1Y
-26.2%
Narrative Update • Jun 15

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
FTLF
US$11.27
FitLife Brands
7D
8.9%
1Y
-13.2%
OLPX
US$2.05
Olaplex Holdings
7D
0.5%
1Y
36.7%
Narrative Update • Jun 09

OLPX: Henkel Cash Deal And Mixed Revisions Will Test Earnings Durability

Analysts have lifted their average price target on Olaplex Holdings stock to $2.00 from about $1.72, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples drawn from recent research. Analyst Commentary Recent research on Olaplex reflects a mix of higher price targets and more cautious stances, with several firms revisiting their assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.
KVUE
US$18.12
Kenvue
7D
-0.7%
1Y
-15.2%
Narrative Update • Jun 08

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Analysts slightly lifted their fair value estimate for Kenvue to $19.50, a modest move supported by small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, even as recent Street research from Citi, Barclays and UBS reflects more cautious price targets. Analyst Commentary Recent price target trims of around $1 from several firms signal that the Street is fine tuning expectations rather than making a wholesale shift in its view on Kenvue.
UPXI
US$0.91
Upexi
7D
-16.0%
1Y
-90.9%